BioSpace News Archive

Ocuphire Pharma, Inc. announced that it has completed enrollment in the MIRA-4 trial evaluating the safety and efficacy of Nyxol® eye drops to reverse pharmacologically-induced mydriasis in 23 pediatric subjects.

Inhibikase Therapeutics, Inc. announced that Dr. Milton Werner, Ph.D., President & Chief Executive Officer of Inhibikase, will give an oral presentation at the AD/PD™, Alzheimer’s & Parkinson’s Diseases Conference being held in Barcelona, Spain from March 15-20, 2022.

Pionyr Immunotherapeutics, Inc. announced that the first patient has been dosed in Phase 1b expansion studies investigating PY314 in patients with solid tumors.

Rigel Pharmaceuticals, Inc. announced the publication of data in the American Journal of Hematology from the open label, multicenter, Phase 2 clinical study of fostamatinib in adults with warm antibody autoimmune hemolytic anemia who had failed at least one prior treatment.

“Caraway is developing oral small molecule therapeutics that enhance lysosomal function to accelerate clearance of toxic materials, such as proteins, oligomers and lipids, that accumulate in many genetically defined neurodegenerative and rare diseases,” said Williams.

Inscopix, Inc. announced that it has launched a new application for its miniscope-based platforms to investigate neuronal activity and blood flow simultaneously, a novel research method that may prove critical to studying neurovascular dynamics in the context of aging, dementia, stroke and other debilitating diseases.

Digestome Therapeutics, a biotech company developing first-in-class therapeutics that stimulate the central nervous system via the gut-brain-axis, announced that the first patient has been enrolled in a Phase 1 clinical trial investigating DGX-001.

PROCEPT® BioRobotics reported financial results for the fourth quarter and full year ended December 31, 2021.

Researchers at City of Hope, one of the largest cancer research and treatment organizations in the United States, have data pointing to the limitations of Signatera, a popular liquid biopsy or blood draw test that is used to detect the recurrence of colorectal cancer in patients who have had their disease surgically removed.

The global smart healthcare products market is expected to witness growth at a CAGR of 9.2% during the forecast period 2022 to 2030 due to advancements in smart syringes and smart pills for remote patient monitoring.